NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Apixaban: Low-Dose Long-Term Use After Provoked VTE Shows Benefits
Christopher Cannon/LinkedIn
Sep 21, 2025, 16:25

Apixaban: Low-Dose Long-Term Use After Provoked VTE Shows Benefits

Christopher Cannon, Editor in Chief, Harvard Health Publishing, shared a post on LinkedIn:

“Low-dose Apixaban long-term following a “provoked” VTE is beneficial.

I think that practice will change – from stopping anticoagulation after a period of initial treatment, to reducing to 1/2 dose for long-term prevention.

This has been my practice for “unprovoked” DVT/PE based on a host of other trials, but this study now extends this: it looked at those with a transient factor like surgery, trauma or immobility – but with an enduring risk factor: ASCVD, Obesity, Heart failure (systolic, diastolic, or combined, lung disease(COPD, asthma, interstitial lung disease), Chronic kidney disease (eGFR <60 mL/min/1.72m2)

Chronic inflammatory/autoimmune disorder (inflammatory arthritis, vasculitis, inflammatory bowel disease, chronic infection) or Persistent immobility. That covers a lot of patients.

Younger, healthy patients who have “provoked” VTE. e.g., post surgery or immobility- they would be ones where stopping after an initial period of anticoagulation is reasonable.

Congratulations Gregory Piazza, Samuel Z. Goldhaber, MD and colleagues!”

Read full article here.

Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism

Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison

Apixaban: Low-Dose Long-Term Use After Provoked VTE Shows Benefits

Stay updated with Hemostasis Today.

 

Anticoagulation Antoine Bejjani Apixaban Arvind K. Pandey Behnood Bikdeli Candrika D Khairani Cardiology Christopher Cannon Clinical Trial Darsiya Krishnathasan Gregory Piazza Health Hematology Hemostasis Hemostasis Today Low-Dose Long-Term Use Medicine Ruth H. Morrison VTE
NewsFeed